Critical Comparison: Quantum Genomics (OTCMKTS:QNNTF) vs. TELA Bio (NASDAQ:TELA)

TELA Bio (NASDAQ:TELA) and Quantum Genomics (OTCMKTS:QNNTF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Insider and Institutional Ownership

94.4% of TELA Bio shares are held by institutional investors. 4.7% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for TELA Bio and Quantum Genomics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1	1	3	0	2.40
Quantum Genomics	0	0	0	0	0.00

TELA Bio presently has a consensus price target of $3.25, indicating a potential upside of 262.48%. Given TELA Bio’s stronger consensus rating and higher possible upside, analysts plainly believe TELA Bio is more favorable than Quantum Genomics.

Profitability

This table compares TELA Bio and Quantum Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TELA Bio	-50.61%	-272.13%	-53.25%
Quantum Genomics	N/A	N/A	N/A

Volatility and Risk

TELA Bio has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Quantum Genomics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.

Earnings and Valuation

This table compares TELA Bio and Quantum Genomics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$69.30 million	0.52	-$37.84 million	($0.89)	-1.01
Quantum Genomics	N/A	N/A	N/A	N/A	N/A

Quantum Genomics has lower revenue, but higher earnings than TELA Bio.

Summary

TELA Bio beats Quantum Genomics on 7 of the 10 factors compared between the two stocks.

About TELA Bio

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

About Quantum Genomics

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.